$41.92
+0.55%XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
| Declaration | Ex-Date | Payment Date | Dividend | Adjusted | Frequency | Growth |
|---|---|---|---|---|---|---|
| No dividend payment history available | ||||||
Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.
FCF insufficient to cover dividends. Company relying on borrowing, asset sales, or cash reserves to maintain payout. Unsustainable long-term.
Flat or modest dividend growth. Company maintaining dividend but not increasing aggressively. Monitor whether due to business maturity or temporary headwinds.
Sustainable dividend with adequate coverage. Some areas for improvement but overall appears safe for dividend investors.
Unsustainable dividend: Company paying out more than it generates in earnings or free cash flow. Dividend cut highly probable unless management takes corrective action or earnings recover dramatically.
Continue your XOMA research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.